



Aggie B. Lee

Counsel

515 South Flower Street,
Forty-Second Floor
Los Angeles, CA 90071-2223

D 213.430.3402
F 213.430.3409
201 Mission Street,
Suite 2310
San Francisco, CA 94105-1839

D 415.617.2107

F 415.617.2409

aggie.lee@tuckerellis.com

Aggie Lee handles complex commercial litigation with an emphasis on pharmaceutical and medical device litigation.

Aggie regularly defends manufacturers in coordinated state proceedings and federal multidistrict litigation, as well as individual cases involving product liability, personal injury, and consumer protection claims. She enjoys working with medical experts and investigating the medical issues unique to each case.

Before joining Tucker Ellis, Aggie was a law clerk with the Los Angeles Superior Court, Appellate Division, where she handled criminal and civil appeals and writs.

Born and raised in Southern California, Aggie enjoys international travel, yoga, and classic films from Hollywood's golden age. She spent three years in Nanjing, China, and traveled extensively through East and Southeast Asia. While in Nanjing, she attended the Johns Hopkins University-Nanjing University Center for Chinese and American Studies, where the curriculum included Chinese civil and criminal law courses taught entirely in Mandarin Chinese.

Education

- University of California, Hastings College of the Law (J.D., 2003); Hastings Communications and Entertainment Law Journal
- The Hopkins-Nanjing Center (Graduate Certificate in Chinese and American Studies, 2011)
- University of California, Berkeley (B.A., English, 1999)

State Admissions

- California, 2003

Federal Admissions

- United States Court of Appeals, Ninth Circuit
- United States District Court, Central District of California
- United States District Court, Eastern District of California
- United States District Court, Northern District of California
- United States District Court, Southern District of California

Service Areas

- [Life Sciences Litigation](#)
- [Health & Life Sciences](#)

Publications & Events

PUBLICATIONS

- “The Matrix Preempted,” *Mondaq* (March 2017), [Drug & Device Law Blog](#) (March 2017)